The COMPARZ results complement the PISCES data – continued 1 The most important symptom which influenced this preference –Pazopanib: Less fatigue (21
{"Image DocumentName": "The COMPARZ results complement the PISCES data \u2013 continued1", "Image ImageDescription": "The most important symptom which influenced this preference. Pazopanib: Less fatigue (21 of the 80 patients who preferred pazopanib) Sunitinib: Less diarrhoea (6 of the 25 patients who preferred sunitinib) The most common adverse events (all grade) reported in \u226530% of patients receiving pazopanib and sunitinib respectively were: diarrhoea 42% vs. 32%, nausea 33% vs. 30% and fatigue 29% vs. 30% 1. Escudier BJ, Porta C, Bono P, et al. Abstract and oral presentation at the American Society of Clinical Oncology Annual Congress J Clin Oncol 2012; 30 (suppl.): Abstract CRA4502.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}